Abstract
Background: Alzheimer’s disease (AD) pathogenesis is primarily hallmarked by the production and accumulation of amyloid beta (Aβ) peptide. Along with the understanding of the neurodegenerative disease progression and its pathophysiological mechanisms, development of anti-Aβ targeted effective therapeutics is essential for AD management. Numerous therapeutic approaches targeting the production, toxicity and removal of Aβ are being attempted worldwide. Prime need is to design inhibitors which can slow down the Aβ aggregation process in a physiological environment. Bexarotene (targretin) is the first of the U.S. Food and Drug Administration approved oral retinoid X receptors (RXR)-selective retinoids, or rexinoids. It is effectively used for the treatment of advanced, refractory cutaneous T cell lymphoma, and also reportedly reduces Aβ levels in AD mouse models. Administration of bexarotene facilitates intracellular Aβ clearance via RXR regulated apolipoprotein E (ApoE) production.
Objective: To the best of our knowledge, this is the first structural attempt to find binding interactions of the drug bexarotene with monomeric Aβ peptide. Method: We checked binding possibilities of bexarotene by using structural bioinformatics method. Results: We found in our study the basic amino acids His13 and Lys 16 of Aβ peptide to be crucial for the interaction with bexarotene. Conclusion: We speculate that direct binding of bexarotene to free Aβ peptide may lessen the concentration of free Aβ peptides in the brain and hamper the propensity of the peptide’s clumping and aggregating behavior. Further experimental validation of the results of this study would be required for its therapeutic success.Keywords: Alzheimer's therapeutics, amyloid beta peptide, bexarotene, docking, interactions.
Current Alzheimer Research
Title:Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study
Volume: 14 Issue: 3
Author(s): Zeenat Mirza and Mohd Amin Beg
Affiliation:
Keywords: Alzheimer's therapeutics, amyloid beta peptide, bexarotene, docking, interactions.
Abstract: Background: Alzheimer’s disease (AD) pathogenesis is primarily hallmarked by the production and accumulation of amyloid beta (Aβ) peptide. Along with the understanding of the neurodegenerative disease progression and its pathophysiological mechanisms, development of anti-Aβ targeted effective therapeutics is essential for AD management. Numerous therapeutic approaches targeting the production, toxicity and removal of Aβ are being attempted worldwide. Prime need is to design inhibitors which can slow down the Aβ aggregation process in a physiological environment. Bexarotene (targretin) is the first of the U.S. Food and Drug Administration approved oral retinoid X receptors (RXR)-selective retinoids, or rexinoids. It is effectively used for the treatment of advanced, refractory cutaneous T cell lymphoma, and also reportedly reduces Aβ levels in AD mouse models. Administration of bexarotene facilitates intracellular Aβ clearance via RXR regulated apolipoprotein E (ApoE) production.
Objective: To the best of our knowledge, this is the first structural attempt to find binding interactions of the drug bexarotene with monomeric Aβ peptide. Method: We checked binding possibilities of bexarotene by using structural bioinformatics method. Results: We found in our study the basic amino acids His13 and Lys 16 of Aβ peptide to be crucial for the interaction with bexarotene. Conclusion: We speculate that direct binding of bexarotene to free Aβ peptide may lessen the concentration of free Aβ peptides in the brain and hamper the propensity of the peptide’s clumping and aggregating behavior. Further experimental validation of the results of this study would be required for its therapeutic success.Export Options
About this article
Cite this article as:
Mirza Zeenat and Beg Amin Mohd, Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study, Current Alzheimer Research 2017; 14 (3) . https://dx.doi.org/10.2174/1567205013666161114115344
DOI https://dx.doi.org/10.2174/1567205013666161114115344 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
“Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Drug Delivery Letters Biology of the Interleukin-9 Pathway and its Therapeutic Potential for the Treatment of Asthma
Inflammation & Allergy - Drug Targets (Discontinued) SRLVs: A Genetic Continuum of Lentiviral Species in Sheep and Goats with Cumulative Evidence of Cross Species Transmission
Current HIV Research Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Solid Lipid Nanoparticles and Nanostructured Lipid Carriers – Innovative Generations of Solid Lipid Carriers
Current Drug Delivery Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer
Current Clinical Pharmacology Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease
Current Topics in Medicinal Chemistry HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Lymphoproliferative Lesions in IgG4-Related Disease
Current Immunology Reviews (Discontinued) Zebrafish as a Model for the Study of the Phase II Cytosolic Sulfotransferases
Current Drug Metabolism In or Out Stemness: Comparing Growth Factor Signalling in Mouse Embryonic Stem Cells and Primordial Germ Cells
Current Stem Cell Research & Therapy Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Current Drug Targets Curcumin and its Formulations: Potential Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Molecular Bases of the Self-Renewal and Differentiation of Leukemic Stem Cells
Current Cancer Therapy Reviews A Homodimer Model Can Resolve the Conundrum as to How Cytochrome P450 Oxidoreductase and Cytochrome b5 Compete for the Same Binding Site on Cytochrome P450c17
Current Protein & Peptide Science Current Evaluation of the Millennium Phytomedicine- Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine
Current Medicinal Chemistry Statins as Either Immunomodulators or Anti-Cancer Drugs: Functional Activities on Tumor Stromal Cells and Natural Killer Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Novel Thiazine Substituted 9-Anilinoacridines: Synthesis, Antitumour Activity and Structure Activity Relationships
Anti-Cancer Agents in Medicinal Chemistry